Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

Novartis recommends new treatments for Tekturna patients with kidney disorders

Filed April 23rd, 2012 Laurie

Swiss drug maker Novartis is urging patients in the U.S. taking its drug Tekturna (aliskiren) to discuss potential alternative treatments as the Food and Drug Administration conducts a more thorough review of the blood pressure drug.

According to a statement from Novartis, the company is also halting the sales and marketing of its drug Valturna, a combination of aliskiren and valsartan. The decision is based on the FDA’s ongoing review of the failed clinical drug trial, ALTITUDE, which was halted after numerous serious side effects were reported among people taking Tekturna and an ACE inhibitor drug to regulate high blood pressure levels (hypertension).

Patients taking these drugs in combination are more likely to suffer adverse side effects, specifically to the kidneys.

In advising all patients on Tekturna to consult with their prescribing physicians, Novartis is also urging patients with prior renal problems to stop taking the drug once an alternative treatment is found. Labels of Tekturna have now been updated to indicate its warnings to patients with prior kidney troubles.

Valturna will only be available in the U.S. until mid-July and patients taking the drug are advised to consult with their doctors to determine their next step in their treatment of hypertension.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!